|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 53.63 USD | +1.69% |
|
-6.01% | +74.12% |
| 11-06 | Genmab: Strong profit beat but guidance unchanged; time to book profits |  |
| 11-06 | Goldman Sachs raises price target for Genmab to DKK4,500 (4,450), reiterates buy - BN | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GENMAB A/S | Bio Therapeutic Drugs | +1.69% | -6.01% | +74.12% | +87.12% | +15.43% | 33.29B |
-
|
-
|
-
|
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Charts Genmab A/S
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
